enfortumab,enfortumab vedotin
astellas,seagen
['ev-301', 'urothelial', 'enfortumab']
#asco22 news: updated ev-301 data show the survival advantage conferred by enfortumab vedotin over standard chemo is maintained over time in pretreated advanced urothelial cancer. read our report of the poster by et al 
Medicine Matters #oncology publishes the latest news, commentary, research, and educational resources in a range of topics across oncology.